Tempus AI, Inc. is revolutionizing healthcare genomics with AI and data partnerships. Click here to read an analysis on TEM ...

Tempus' FDA-approved xT CDx test is being used as an investigational assay in Verastem's global Phase 3 RAMP-301 clinical trial.

From surgical precision tools to real-time diagnostics, brain-responsive stimulation, and multi-disease detection systems, AI ...

From trial phases to personalized care, here’s how healthcare providers can navigate cancer clinical trials and guide ...

Tempus AI Inc. TEM during the first quarter secured a multi-million dollar deal to build “the world’s largest foundation model for oncology.” “And this is big for a few reasons,” said ...

CHICAGO (AP) — CHICAGO (AP) — Tempus AI Inc. (TEM) on Tuesday reported a loss of $68 million in its first quarter. On a per-share basis, the Chicago-based company said it had a loss of 40 cents.

While Tempus is at the forefront of the intersection between AI and oncology, this investment requires higher risk-tolerance at the moment since the business is still unprofitable. Before you buy ...

Tempus inks $200 million in AstraZeneca, Pathos AI deals for oncology model Tempus assembles advisory board to guide oncology research Lefkofsky, touting strong financials for Tempus, paints a ...

characterizes itself as possessing what it "consider[s] to be one of the largest libraries of clinical and molecular oncology data in the world." It's with this resource that Tempus is able to ...

For the Pathos P300-02-001 study, Tempus screened and enrolled the trial’s first and second patients at Nebraska Cancer Specialists and Oncology Consultants within weeks. “The integration of ...